135 related articles for article (PubMed ID: 11551512)
21. Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.
Homer KL; Wanstall JC
Br J Pharmacol; 2002 Dec; 137(7):1071-81. PubMed ID: 12429580
[TBL] [Abstract][Full Text] [Related]
22. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits the spontaneous contractions of isolated pregnant rat myometrium.
Cetin A; Kaya T; Demirkoprulu N; Karadas B; Duran B; Cetin M
J Pharmacol Sci; 2004 Jan; 94(1):19-24. PubMed ID: 14745113
[TBL] [Abstract][Full Text] [Related]
23. Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes.
Wang H; Kohr MJ; Traynham CJ; Ziolo MT
J Mol Cell Cardiol; 2009 Aug; 47(2):304-14. PubMed ID: 19345227
[TBL] [Abstract][Full Text] [Related]
24. Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel.
Dismuke WM; Sharif NA; Ellis DZ
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3353-9. PubMed ID: 19234350
[TBL] [Abstract][Full Text] [Related]
25. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets.
Friebe A; Müllershausen F; Smolenski A; Walter U; Schultz G; Koesling D
Mol Pharmacol; 1998 Dec; 54(6):962-7. PubMed ID: 9855623
[TBL] [Abstract][Full Text] [Related]
26. YC-1, a novel activator of platelet guanylate cyclase.
Ko FN; Wu CC; Kuo SC; Lee FY; Teng CM
Blood; 1994 Dec; 84(12):4226-33. PubMed ID: 7527671
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of YC-1-induced activation of soluble guanylyl cyclase.
Friebe A; Koesling D
Mol Pharmacol; 1998 Jan; 53(1):123-7. PubMed ID: 9443939
[TBL] [Abstract][Full Text] [Related]
28. YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components.
Martin E; Lee YC; Murad F
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):12938-42. PubMed ID: 11687640
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents.
Lee FY; Lien JC; Huang LJ; Huang TM; Tsai SC; Teng CM; Wu CC; Cheng FC; Kuo SC
J Med Chem; 2001 Oct; 44(22):3746-9. PubMed ID: 11606139
[TBL] [Abstract][Full Text] [Related]
30. Investigation of the cellular mechanism of inhibition of formyl-methionyl-leucyl-phenylalanine-induced superoxide anion generation in rat neutrophils by 2-benzyloxybenzaldehyde.
Wang JP; Chang LC; Lin YL; Hsu MF; Chang CY; Huang LJ; Kuo SC
Biochem Pharmacol; 2003 Apr; 65(7):1043-51. PubMed ID: 12663040
[TBL] [Abstract][Full Text] [Related]
31. The design and synthesis of YC-1 analogues as probes for soluble guanylate cyclase.
Hering KW; Artz JD; Pearson WH; Marletta MA
Bioorg Med Chem Lett; 2006 Feb; 16(3):618-21. PubMed ID: 16326101
[TBL] [Abstract][Full Text] [Related]
32. Investigation of the vasorelaxant effects of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1) and diethylamine/nitric oxide (DEA/NO) on the human radial artery used as coronary bypass graft.
Berkan O; Bagcivan I; Kaya T; Yildirim K; Yildirim S; Doğan K
Can J Physiol Pharmacol; 2007 May; 85(5):521-6. PubMed ID: 17632587
[TBL] [Abstract][Full Text] [Related]
33. Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition.
Garthwaite G; Goodwin DA; Neale S; Riddall D; Garthwaite J
Mol Pharmacol; 2002 Jan; 61(1):97-104. PubMed ID: 11752210
[TBL] [Abstract][Full Text] [Related]
34. An evolutionarily conserved mechanism for sensitization of soluble guanylyl cyclase reveals extensive nitric oxide-mediated upregulation of cyclic GMP in insect brain.
Ott SR; Delago A; Elphick MR
Eur J Neurosci; 2004 Sep; 20(5):1231-44. PubMed ID: 15341595
[TBL] [Abstract][Full Text] [Related]
35. Activation of soluble guanylyl cyclase inhibits estradiol production and cyclic AMP accumulation from cultured rat granulosa cells.
Tafoya MA; Chen JY; Stewart RL; Lapolt PS
Fertil Steril; 2004 Oct; 82 Suppl 3():1154-9. PubMed ID: 15474089
[TBL] [Abstract][Full Text] [Related]
36. YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway.
Hsu HK; Juan SH; Ho PY; Liang YC; Lin CH; Teng CM; Lee WS
Biochem Pharmacol; 2003 Jul; 66(2):263-71. PubMed ID: 12826268
[TBL] [Abstract][Full Text] [Related]
37. The blockade of formyl peptide-induced respiratory burst by 2',5'-dihydroxy-2-furfurylchalcone involves phospholipase D signaling in neutrophils.
Wang JP; Chang LC; Hsu MF; Lin CN
Naunyn Schmiedebergs Arch Pharmacol; 2003 Sep; 368(3):166-74. PubMed ID: 12928764
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of human neutrophil function by tolfenamic acid involves inhibition of Ca2+ influx.
Kankaanranta H; Wuorela H; Siltaloppi E; Vuorinen P; Vapaatalo H; Moilanen E
Eur J Pharmacol; 1995 Sep; 291(1):17-25. PubMed ID: 8549643
[TBL] [Abstract][Full Text] [Related]
39. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1.
Nakane M; Hsieh G; Miller LN; Chang R; Terranova MA; Moreland RB; Kolasa T; Brioni JD
Int J Impot Res; 2002 Apr; 14(2):121-7. PubMed ID: 11979328
[TBL] [Abstract][Full Text] [Related]
40. A point-mutated guanylyl cyclase with features of the YC-1-stimulated enzyme: implications for the YC-1 binding site?
Friebe A; Russwurm M; Mergia E; Koesling D
Biochemistry; 1999 Nov; 38(46):15253-7. PubMed ID: 10563809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
